BenevolentAI program for treatment of neurological disorders

Saniona and BenevolentAI are working together in a drug discovery and development collaboration. The collaboration focuses on research of new small molecule therapeutics for neurological disorders, using Saniona’s expertise in ion channels and related technology platforms. The program is in the late drug discovery phase.